Thao Dang
Executive Director, Oncology Clinical Development Gilead Sciences
Seminars
Tuesday 13th October 2026
TROP2 ADC–Immunotherapy Combinations: Clinical Evidence, Emerging Strategies & Future Opportunities
6:15 pm
- Contextualizing ADC combinations as the future of effective clinical approaches as more ADCs advance to standard of care oncology settings
- Exploring ongoing work into Trodelvy-immunotherapy clinical combinations in breast, urothelial and lung cancers
- Exploring rationale and strategy for novel combinations to maximize the therapeutic potential and patient impact of ADCs